Enhancing hepatitis C treatment outcomes among people who use drugs

Evidence to guide future practice and policy
Insights zone 1 (I1)
In programme
Thursday, 24 October, 2019 - 13:20 to 14:50
View presentations

Chair

Matheï
Catharina
  • KU Leuven
  • Belgium
Dunlop
Adrian
  • Hunter New England Local Health District
  • Australia

Tracks

Keywords

Presentations

  • Plenary session
  • Poster session
  • Big debate
  • Structured session
  • Workshop
  • Oral presentation session
  • Short communication session
  • Poster guided tour

Thursday, 24 October

13:30
Oral presentation

HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care

13:30 to 13:45
Insights zone 1 (I1)
Matthew Hickman
13:45
Oral presentation

Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany

13:45 to 14:00
Insights zone 1 (I1)
Bernd Schulte
14:00
Oral presentation

Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme

14:00 to 14:15
Insights zone 1 (I1)
Brian Conway
14:15
Oral presentation

Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST

14:15 to 14:30
Insights zone 1 (I1)
Tina McHugh
14:30
Oral presentation

The cost-effectiveness of an HCV outreach intervention for at risk populations in London

14:30 to 14:45
Insights zone 1 (I1)
Zoe Ward
Oral presentation

Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data

14:30 to 14:45
Insights zone 1 (I1)
Norah Palmateer
View the programme